Zimmer Holdings, Inc. to Combine with Biomet, Inc. in Transaction Valued at $13.35 Billion

- Creates Leading Musculoskeletal Innovator to Shape Solutions for Evolving Healthcare Industry
- Double-Digit Accretion to Zimmer's Adjusted Diluted Earnings Per Share in First Year
- Zimmer to Host Conference Call at 8:00 AM ET Today

WARSAW, Ind., April 24, 2014 - Zimmer Holdings, Inc. (NYSE and SIX: ZMH) ("Zimmer" or the "Company") and Biomet, Inc.'s parent company ("Biomet") today announced that their respective Boards of Directors have approved a definitive agreement under which Zimmer will acquire Biomet in a cash and stock transaction valued at approximately $13.35 billion, including the assumption of net debt. The transaction, which is subject to customary closing conditions and regulatory approvals, is expected to close in the first quarter of 2015.

Read more: Zimmer Holdings Inc ( ZMH )

Chindex Announces Receipt of Superior Proposal

April 14, 2014 - Chindex International, Inc. (CHDX) ("Chindex" or the "Company"), an American healthcare company providing services in China through the operations of United Family Healthcare, a network of private primary care hospitals and affiliated ambulatory clinics, today announced the receipt of an offer from a financial bidder to acquire all of the outstanding shares of Chindex common stock for $23 per share in cash.

Read more: Chindex International Inc ( CHDX )

Baxano Surgical Receives 510(k) Clearance for the Avance MIS Pedicle Screw System

April 10, 2014 -  Baxano Surgical, Inc. (BAXS), a medical device company focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the lumbar spine, today announced that it has received U.S. Food and Drug Administration 510(k) clearance (k133743) of its Avance(TM) MIS Pedicle Screw System, which may be used as an adjunct to fusion in numerous degenerative and complex spinal pathologies.

Read more: Baxano Surgical Inc ( BAXS )

IsoRay Announces World's First Human Prostate Implant Utilizing Cesium-131 Seeds and C4 Imaging's Positive Signal MRI Markers

Dr. Steven Frank of MD Anderson Performed the First Implant

Apr 7, 2014) - IsoRay Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced the first prostate cancer implant combining IsoRay's Cesium-131 seeds with C4 Imaging's Sirius® positive signal MRI markers.

IsoRay CEO Dwight Babcock commented, "We are very excited to have our Cesium-131 isotope seeds chosen to partner with C4 Imaging's innovative positive signal MRI markers in the treatment of prostate cancer. By combining two of the newest technologies available in brachytherapy, we hope to demonstrate superior outcomes with the goal of improving patient lives.

Read more: IsoRay Inc ( ISR )

Escalon® Medical Corp. Receives FDA 510(k) Clearance for the Sonomed Escalon VuPad™

An innovation in ultrasound you can see and touch

Escalon Medical Corp. (ESMC) today announced that it received U.S. Food and Drug Administration (FDA) 510(k) clearance for its new tablet-based ultrasound imaging system, the Sonomed Escalon VuPad™.

The VuPad™ combines Sonomed Escalon's superior UBM and newly enhanced B-scan image quality with an ultra-high-resolution screen that has 25% larger viewing area than other portable ultrasound devices.  Proprietary Enhanced Focus Rendering™ enables capture of both crisp still images and high-resolution video clips that can be reviewed frame-by-frame.  The VuPad™ is also remarkably easy to use, thanks to intuitively designed touch screen controls.

Read more: Escalon Medical Corp ( ESMC )